Allo-HSCT With Alternative Donor in Treatment of Hematologic Malignancy

Summary

The purpose of this study is to compare the efficacy of allogeneic hematopoietic stem cell transplantation (allo-HSCT) from matched sibling donor (MSD),matched unrelated donor (MUD) and haploidentical related donors(HRD) in the treatment of hematologic malignancy.

Conditions

• Acute Leukemia
• Chronic Myeloid Leukemia
• Myelodysplastic Syndrome

Interventions

PROCEDURE

HSCT from MSD

HSCT from MSD is the first choice for the patients who have HLA-matched sibling donors.

PROCEDURE

HSCT from MUD

HSCT from MUD is the second choice for the patients who don't have HLA-matched sibling donors but have HLA-matched unrelated donors.

PROCEDURE

HSCT from HRD

HSCT from HRD is the choice for the patients who have neither HLA-matched sibling donors nor HLA-matched unrelated donors.

DRUG

Cyclosporin A

CsA is used in all the patients for GVHD prophylaxis.

DRUG

Methotrexate

MTX is used in all the patients for GVHD prophylaxis.

DRUG

Antithymocyte globulin

ATG is used in the patients receiving HSCT from MUD and HRD for GVHD prophylaxis.In MUD group,total ATG doses is 7 mg/kg;In HRD group,total ATG doses is 7.5 or 10 mg/kg.

DRUG

Mycophenolate mofetil

MMF is used in the patients receiving HSCT from MSD and HRD for GVHD prophylaxis.

Sponsors & Collaborators

• Guangdong Provincial People's Hospital

  collaborator OTHER

• Third Affiliated Hospital, Sun Yat-Sen University

  collaborator OTHER

• Guangzhou General Hospital of Guangzhou Military Command

  collaborator OTHER

• Guangzhou First People's Hospital

  collaborator OTHER

• Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

  collaborator OTHER

• Zhujiang Hospital

  collaborator OTHER

• Tongji Hospital

  collaborator OTHER

• Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

  collaborator OTHER

• Fujian Medical University Union Hospital

  collaborator OTHER

• First Affiliated Hospital of Guangxi Medical University

  collaborator OTHER

• Xiangya Hospital of Central South University

  collaborator OTHER

• Nanfang Hospital, Southern Medical University

  lead OTHER

Principal Investigators

• Qifa Liu · Nanfang Hospital, Southern Medical University

Study Design

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

18 Years

Max Age

60 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2015-06-30

Primary Completion

2020-01-31

Completion

2020-02-29

Countries

• China

Study Locations